Literature DB >> 31825656

Activation of the PKA signaling pathway stimulates oxalate transport by human intestinal Caco2-BBE cells.

Donna Arvans1, Altayeb Alshaikh1, Mohamed Bashir1, Christopher Weber2, Hatim Hassan1.   

Abstract

Most kidney stones are composed of calcium oxalate, and small increases in urine oxalate enhance the stone risk. The mammalian intestine plays a crucial role in oxalate homeostasis, and we had recently reported that Oxalobacter-derived factors stimulate oxalate transport by human intestinal Caco2-BBE (C2) cells through PKA activation. We therefore evaluated whether intestinal oxalate transport is directly regulated by activation of the PKA signaling pathway. To this end, PKA was activated with forskolin and IBMX (F/I). F/I significantly stimulated (3.7-fold) [14C]oxalate transport by C2 cells [≥49% of which is mediated by the oxalate transporter SLC26A6 (A6)], an effect completely blocked by the PKA inhibitor H89, indicating that it is PKA dependent. PKA stimulation of intestinal oxalate transport is not cell line specific, since F/I similarly stimulated oxalate transport by the human intestinal T84 cells. F/I significantly increased (2.5-fold) A6 surface protein expression by use of immunocytochemistry. Assessing [14C]oxalate transport as a function of increasing [14C]oxalate concentration in the flux medium showed that the observed stimulation is due to a F/I-induced increase (1.8-fold) in Vmax and reduction (2-fold) in Km. siRNA knockdown studies showed that significant components of the observed stimulation are mediated by A6 and SLC26A2 (A2). Besides enhancing A6 surface protein expression, it is also possible that the observed stimulation is due to PKA-induced enhanced A6 and/or A2 transport activity in view of the reduced Km. We conclude that PKA activation positively regulates oxalate transport by intestinal epithelial cells and that PKA agonists might therapeutically impact hyperoxalemia, hyperoxaluria, and related kidney stones.

Entities:  

Keywords:  PKA; SLC26A2; SLC26A6; T84 cells; intestinal oxalate transport

Mesh:

Substances:

Year:  2019        PMID: 31825656      PMCID: PMC7052606          DOI: 10.1152/ajpcell.00135.2019

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  43 in total

1.  Primary hyperoxaluria: from gene defects to designer drugs?

Authors:  Christopher J Danpure
Journal:  Nephrol Dial Transplant       Date:  2005-06-14       Impact factor: 5.992

2.  Urinary oxalate excretion increases with body size and decreases with increasing dietary calcium intake among healthy adults.

Authors:  J Lemann; J A Pleuss; E M Worcester; L Hornick; D Schrab; R G Hoffmann
Journal:  Kidney Int       Date:  1996-01       Impact factor: 10.612

3.  Regulated transport of sulfate and oxalate by SLC26A2/DTDST.

Authors:  John F Heneghan; Arash Akhavein; Maria J Salas; Boris E Shmukler; Lawrence P Karniski; David H Vandorpe; Seth L Alper
Journal:  Am J Physiol Cell Physiol       Date:  2010-03-10       Impact factor: 4.249

4.  Hyperoxaluria is a long-term consequence of Roux-en-Y Gastric bypass: a 2-year prospective longitudinal study.

Authors:  Branden G Duffey; Shaheen Alanee; Renato N Pedro; Bryan Hinck; Carly Kriedberg; Sayeed Ikramuddin; Todd Kellogg; Michelle Stessman; Angela Moeding; Manoj Monga
Journal:  J Am Coll Surg       Date:  2010-07       Impact factor: 6.113

5.  Adenosinergic signaling inhibits oxalate transport by human intestinal Caco2-BBE cells through the A2B adenosine receptor.

Authors:  Daniel Jung; Altayeb Alshaikh; Sireesha Ratakonda; Mohamed Bashir; Ruhul Amin; Sohee Jeon; Jan Stevens; Sapna Sharma; Wahaj Ahmed; Mark Musch; Hatim Hassan
Journal:  Am J Physiol Cell Physiol       Date:  2018-07-18       Impact factor: 4.249

6.  Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass.

Authors:  Wayne K Nelson; Scott G Houghton; Dawn S Milliner; John C Lieske; Michael G Sarr
Journal:  Surg Obes Relat Dis       Date:  2005-08-26       Impact factor: 4.734

Review 7.  Oxalate, inflammasome, and progression of kidney disease.

Authors:  Theresa Ermer; Kai-Uwe Eckardt; Peter S Aronson; Felix Knauf
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

8.  Extracellular nucleotides inhibit oxalate transport by human intestinal Caco-2-BBe cells through PKC-δ activation.

Authors:  Ruhul Amin; Sapna Sharma; Sireesha Ratakonda; Hatim A Hassan
Journal:  Am J Physiol Cell Physiol       Date:  2013-04-17       Impact factor: 4.249

9.  Hyperoxaluria in patients with recurrent calcium oxalate calculi: dietary and other risk factors.

Authors:  N A Laminski; A M Meyers; M Kruger; M I Sonnekus; L P Margolius
Journal:  Br J Urol       Date:  1991-11

10.  24-h uric acid excretion and the risk of kidney stones.

Authors:  G C Curhan; E N Taylor
Journal:  Kidney Int       Date:  2007-12-05       Impact factor: 10.612

View more
  5 in total

1.  Oxalate secretion is stimulated by a cAMP-dependent pathway in the mouse cecum.

Authors:  Jonathan M Whittamore; Marguerite Hatch
Journal:  Pflugers Arch       Date:  2022-08-31       Impact factor: 4.458

Review 2.  Physiological and Pathological Functions of SLC26A6.

Authors:  Juan Wang; Wenkang Wang; Hui Wang; Biguang Tuo
Journal:  Front Med (Lausanne)       Date:  2021-01-21

3.  The role of NHE3 (Slc9a3) in oxalate and sodium transport by mouse intestine and regulation by cAMP.

Authors:  Christine E Stephens; Jonathan M Whittamore; Marguerite Hatch
Journal:  Physiol Rep       Date:  2021-04

4.  The anion exchanger PAT-1 (Slc26a6) does not participate in oxalate or chloride transport by mouse large intestine.

Authors:  Jonathan M Whittamore; Marguerite Hatch
Journal:  Pflugers Arch       Date:  2020-11-17       Impact factor: 3.657

5.  SLC26A6-selective inhibitor identified in a small-molecule screen blocks fluid absorption in small intestine.

Authors:  Onur Cil; Peter M Haggie; Joseph-Anthony Tapia Tan; Amber A Rivera; Alan S Verkman
Journal:  JCI Insight       Date:  2021-06-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.